MAPT and amyloidosis: All of these data are in line with another study where the associations of p-T217 with tau PET, CSF and PET measures of amyloid pathology were tested in comparison to p-T181 [220]; the authors found that CSF p-T217 correlates better than p-T181 with PET measures of tau and amyloid pathologies in AD, and more accurately distinguishes AD from non-AD neurodegenerative disorders, suggesting the benefit of employing CSF p-T217 as a biomarker of AD in clinical practice.